Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

64.37 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
81 82 Next >
Novo Nordisk's Older Generation Weight-Loss Drug Saxenda Associated With Decreased Bone Mass Density, Study Shows
Novo Nordisk's Saxenda study published in JAMA Network Open reveals significant declines in bone density among patients, raising concerns for similar weight loss drugs. 
Via Benzinga
Why Novo Nordisk Shares Are Trading Higher Tuesday
The company's weight loss drug Wegovy has been approved in China, the second most populated country that is estimated to have the world's highest number of overweight individuals, according to... 
Via Benzinga
Novo Nordisk Wins Approval For Its Weight-Loss Drug From China
China approved the sale of Novo Nordisk's Wegovy on Tuesday. The drugmaker also announced a $4.1 billion investment in the U.S. Novo Nordisk stock climbed 3.0% to an all-time high this morning. 
Via Talk Markets
European Stocks Dip As US Market Sentiment Sours
European stocks declined as U.S. market sentiment soured, with the Stoxx 600 index down 0.41% by mid-morning. Novo Nordisk shares rose 1.5% following the approval of its weight loss treatment in... 
Via Talk Markets
A Closer Look at Novo Nordisk's Options Market Dynamics
Via Benzinga
Why Is Regis (RGS) Stock Up 215% Today?
Regis stock is up on Tuesday with heavy trading of RGS shares after it announced a new credit facility to pay of its debts. 
Via InvestorPlace
Jefferies Just Raised Its Price Target on Nvidia (NVDA) Stock
Nvidia stock is up on Tuesday after shares of NVDA got an increased price target from Jefferies analysts alongside praise. 
Via InvestorPlace
Pfizer's Working on the Next Wegovy, but Can It Beat Novo Nordisk?
This is a matchup that the latecomer might not be able to win. 
Via The Motley Fool
NVO Stock: Novo Nordisk Pops as China Approves Wegovy Weight Loss Drug
Novo Nordisk and Eli Lilly dominate the market for GLP-1 drugs, and are racing ahead to produce more of them. 
Via InvestorPlace
Novo Nordisk Surges Nearly 3% After Weight Loss Drug Wegovy Wins Approval in China
Novo Nordisk's weight loss drug Wegovy has received approval in China, representing a notable achievement for the Danish pharmaceutical firm. 
Via Benzinga
Novartis Stock Just Below Innovative Drugmaker's All-Time High; Gets Key Rating Upgrade
Novartis stock is in a buy range after moving past a 103.55 entry in a cup with handle. The buy range extends to 5% above the initial entry. 
Via Investor's Business Daily
Wegovy, Ozempic Maker Novo Nordisk To Invest $4.1B In US Manufacturing, Doubling Plant Size To Meet Surging Demand For Weight Loss Drugs
Novo Nordisk A/S is set to invest $4.1 billion in expanding its U.S. manufacturing operations to meet the increasing demand for its weight loss drugs. 
Via Benzinga
Regeneron Pharmaceuticals' Approach To Improve Quality Of Weight Loss Has Merit: Goldman Sachs
Regeneron Pharmaceuticals released data from a Phase 1 study on garetosmab and trevogrumab at the ADA meeting, showing significant increases in lean mass and reductions in fat mass in healthy... 
Via Benzinga
Will Novo Nordisk Building Fires Serve As A Catalyst For Eli Lilly? Redditors See A Stock Split For US Company 'Very Likely'
Eli Lilly's stock may rise due to supply issues at competitor Novo Nordisk, according to Reddit users. Its weight loss drug and upcoming FDA approval are also factors. Investors are optimistic about... 
Via Benzinga
Exposures Product Safety
ALT Stock Alert: Altimmune Pops on Weight-Loss Drug Findings
Altimmune (ALT) stock is soaring and trending after the company reported data on its GLP-1 weight-loss drug today. 
Via InvestorPlace
7 Strong Buy Blue-Chip Stocks to Keep You in the Green
Consider these seven strong buy blue-chip stocks for steady growth of your investment portfolio, no matter the market situation. 
Via InvestorPlace
Novo Nordisk's Wegovy Demonstrates Greater Weight Loss In Women With Heart Condition
The greater weight loss in women did not result in significantly better improvements in heart failure symptoms. 
Via Benzinga
3 Biotech Stocks to Buy Now: June 2024
These are the three best biotech stocks to buy for long-term returns and portfolio stability due to their target patient populations, 
Via InvestorPlace
Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments
Gilead Sciences faces Wall Street speculation about its potential in the obesity drug market despite its focus on liver treatments. 
Via Benzinga
Lawsuit Could Challenge Trust In Ozempic And Other Popular Weight Loss Drugs
Weight loss drug manufacturers Novo Nordisk and Eli Lilly are being challenged in court. The companies are accused of failing to properly warn patients about associated risks. 
Via Talk Markets
Topics Lawsuit
Exposures Financial Legal
The Best Could Be Yet to Come for Novo Nordisk and Ozempic
Novo Nordisk's stock may look expensive but not if you focus on the long term. 
Via The Motley Fool
Move Aside Ozempic, WeGovy: Denmark's New Drug Just Showed Positive Results For Weightloss
As per the official press release, the 16-week trial aimed to evaluate the safety, tolerability, and clinical effects of the drug called petrelintide. 
Via Benzinga
Nestle Carefully Targets Weight-Loss Drug Users with New Food Line
Nestle's new Vital Pursuit brand targets individuals on weight-loss drugs without mentioning medications on packaging, addressing regulatory concerns and focusing on marketing through social media. 
Via Benzinga
German Drug Developer Evotec Seeks Adviser Input As Takeover Concerns Mount
Evotec consults defense advisers following a significant share price decline, raising concerns about a potential takeover. 
Via Benzinga
Eli Lilly Expands Fight Against Counterfeit Obesity Drug Zepbound With New Legal Actions
Eli Lilly & Co has intensified its fight against counterfeit versions of its popular obesity drug, Zepbound, by initiating additional legal proceedings against companies selling compounded versions of... 
Via Benzinga
7 Stocks With Impressive Earnings Growth: Real or Engineered?
These growth stocks have shown impressive earnings increases but not all earnings growth is the same so investors must pay attention. 
Via InvestorPlace
Eli Lilly Hits All-Time High, Named To Big Cap 20 List: Check These Lists For Best Stocks To Buy
Eli Lilly stock has been on an astounding run. In 2009 its stock sold for 27.21 a share. It closed Tuesday at 891.46, up 3,149% from 2009. 
Via Investor's Business Daily
3 Mega Cap Stock Bargains As Markets Hit All-Time Highs
We ran a screener using Benzinga Pro to filter out three mega-cap stocks that are currently trading at attractive valuations. 
Via Benzinga
Obesity In Children - US Parents Face Tough Time To Access Recommended Treatment, Though Novo Nordisk's Drug Still Sees Strong Demand
U.S. parents face significant barriers to accessing intensive behavioral counseling for childhood obesity, with programs often unavailable, not covered by insurance, and requiring substantial time... 
Via Benzinga
The Best Biotech Stock to Invest $1,000 in Right Now
This stock may not be a slam dunk, but it's looking very promising. 
Via The Motley Fool
< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
81 82 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.